A method for preventing drug-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent selected from a JNK inhibitor, a TRPV modulator, a MET channel inhibitor, and an otoprotectant to the individual in need thereof, wherein the pharmaceutical composition is administered prior to onset of therapy with the drug, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration
FOXO4-DRI 10 mg | Research Use Only This listing provides a 10 mg vial of FOXO4-DRI formulated as a lyophilised solid for laboratory assay development
For Cognition Youd be hard pressed to find a guy more obsessed with the brain-boosting benefits of nootropics than Rogan
Bluum Peptides supplies high-purity SNAP-8, verified by accredited analytical labs in the U
Therefore, any research studies using these ingredients should be carefully designed to monitor for potential adverse reactions, and the concentration of these research compounds should be optimized to balance efficacy and safety
